SERPINF1 and breast carcinoma: For HDACis, a class I HDAC inhibitor termed entinostat could epigenetically activate anti‐angiogenic genes including serpin family F member 1 (SERPINF1) and thrombospondin 2(THBS2) and reduced the formation of vasculogenic mimicry (VM) in triple negative breast cancer, thereby inhibiting tumor metastasis and improving the overall survival of the murine breast cancer models [258].